Enlivex stock trades at 1.25 euros on November 5
Published on 11/05/2026 at 13:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEnlivex Business and Trading Context
- Enlivex is developing Allocetra for late-stage osteoarthritis treatment.
- The company also operates a treasury strategy focused on the Rain prediction markets protocol.
Enlivex stock traded at 1.25 euros on Lang & Schwarz at 13:32 CET on Thursday, November 5, 2026. The quote provides a current European-market reference for the Israeli biotechnology company.
Enlivex says its operating business is focused on the late-stage clinical development of Allocetra, a therapy intended to treat osteoarthritis. The company also describes a treasury strategy centered on Rain, a prediction markets protocol. Further business details are available from Enlivex investor relations.
Investors can follow the real-time quote of Enlivex stock on the company snapshot page. The Nasdaq listing keeps clinical development, financing needs and the treasury strategy central to the investment case.
Enlivex stock at a glance
- Company: Enlivex Ltd.
- ISIN: IL0011319527
- Nasdaq ticker: ENLV
- Lang & Schwarz quote: 1.25 euros at 13:32:14 CET on Thursday, November 5, 2026
- Bid: 1.22 euros
- Ask: 1.27 euros
Nasdaq-listed shares remain exposed to the broader US equity-market backdrop; see current S&P 500 market reports.
More company developments are collected in more news and analyses on Enlivex stock.
